Posters
DA-1726
84th ADA Onsite Poster – DA-1726, a GLP1R/GCGR Dual Agonist, A Promising Approach in Body Composition and Lipid Management
84th ADA ePoster – DA-1726, a GLP1R/GCGR Dual Agonist, A Promising Approach in Body Composition and Lipid Management
83rd ADA Onsite Poster – A Novel GLP1R/GCGR Dual Agonist, DA-1726 Elicits Weight Loss Superior to Semaglutide in Diet-Induced Obese Rats
83rd ADA ePoster – A Novel GLP1R/GCGR Dual Agonist, DA-1726 Elicits Weight Loss Superior to Semaglutide in Diet-Induced Obese Rats
83rd ADA Onsite Poster – Differentiated Metabolic Effects of DA-1726, a Balanced GLP1R/GCGR Dual Agonist
83rd ADA ePoster – Differentiated Metabolic Effects of DA-1726, a Balanced GLP1R/GCGR Dual Agonist
82nd ADA ePoster – DA-1726, a Balanced GLP1R/GCGR Dual Agonist, Effectively Controls both Body Weight and Blood Glucose
82nd ADA ePoster – Therapeutic Potential of DA-1726, a Novel Oxyntomodulin Analogue, in a Diet-Induced NASH Mouse Model
DA-1241
DA-1241, a GPR119 agonist, ameliorates fatty liver through the upregulation of TFEB mediated autophagy
2024 EASL – DA-1241, a GPR119 Agonist, Combined With Semaglutide Synergistically Improved Liver Fibrosis in Mice With CCl4-Induced Liver Fibrosis
2024 EASL – Additive Hepatoprotective Effects of DA-1241, a Novel GPR119 Agonist, in Combination With Semaglutide in the GAN Diet-Induced Obese and Biopsy-Confirmed Mouse Model of MASH
2021 ADA – DA-1241 a novel GPR119 Agonist: Data on Safety Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) from Part 2 of a Phase 1b Multiple Ascending Dose (MAD) Study in Patients with Type 2 Diabetes Mellitus (T2DM)
2021 EASL – DA-1241 a novel GPR119 Agonist: Data on Safety, Tolerability and Pharmacokinetics (PK), from Part 1 of a Phase 1b Multiple Ascending Dose (MAD) Study in Healthy Volunteers (HV)
2021 EASL – DA-1241 a novel GPR119 Agonist: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics -Part 2 of Multiple Ascending Dose Study in Type 2 Diabetes Patients
2021 ADA – DA-1241 a novel GPR119 Agonist: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics -Part 2 of Multiple Ascending Dose Study in Type 2 Diabetes Patients
2020 AASLD – Combination Treatment of a GPR119 Agonist DA-1241 with a DPP4 Inhibitor Synergistically Improves Systemic and Hepatic Inflammation in NASH Mice
2020 ADA – A Novel GPR119 Agonist, DA-1241 Improves Hepatic Inflammation and Fibrosis in Ob-NASH Mice
2020 ADA – A Novel GPR119 Agonist, DA-1241 Reduces Hepatic Inflammation and Fibrosis in Pre-established Diet-induced Obese NASH Mice
2019 ADA – DA-1241 a novel GPR119 Agonist, Improves Hyperglycemia via Inhibition of Hepatic Glucogenesis and Enhancing Glucose Simulated Insulin Secretion via Stimulation of GLP-1 Secretion
2017 ADA – Effects of DA-1241, A Novel GPR119 Agonist, on Lipid Control in Disease Models Mediated by Regulating AMPK/SREBP1c Signaling Path
2015 ADA – Long-term Treatment of DA-1241, a Novel GPR119 Agonist, Improved Glucose Control via Preserved Beta Cell Mass in a Progressive Diabetic Mice Model
